Michael Thomas Henderson, Chief Executive Officer at Apogee Therapeutics, Inc. (APGE), sold 80,000 shares at $56.07 ($4.5M) on 2024-10-02, disclosed to the SEC on 2024-10-04.
Scheduled sale ($4.5M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $56.07 | 30,288 | $1.7M | 37.8% |
| 2 | $56.07 | 30,288 | $1.7M | 37.8% |
| 3 | $56.74 | 9,712 | $551K | 12.2% |
| 4 | $56.74 | 9,712 | $551K | 12.2% |
| Total | $56.23 avg | 80,000 | $4.5M | 100% |
| Filing → |
| SYRE | SELL | 2026-06-23 | $2.0M | — | Filing → |
| APGE | SELL | 2026-06-12 | $1.7M | — | Filing → |
| APGE | SELL | 2026-05-15 | $1.6M | — | Filing → |